MorphoSys AG (NASDAQ:MOR) announces that antitrust regulators have signed off on its collaboration and license agreement with Incyte (NASDAQ:INCY) regarding tatasitamab (MOR208).
The clearance triggers a $750M upfront payment from Incyte and a $150M investment in MOR ADSs.
https://seekingalpha.com/news/3548367-antitrust-watchdog-ok-morphosys-incyte-tafasitamab-partnership
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.